BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
James Webb Space Telescope's mysterious 'little red dots' may be black holes in disguise - 2Experiences in Natural life Protection: Individual Progressives' Excursions
- 3Figure out What Shift Differentials Mean for Your General Attendant Compensation
- 4The Most Vital Crossroads in Olympic History
- 5Smooth out Your Funds: Cash The board Simplified
- Vote In favor of Your Favored Video Conferencing Administration
- What we know about the 'Stranger Things' spinoff — plus the one cast member who guessed it correctly
- Key Little Things That Advantage Old People
- Find Unexpected, yet invaluable treasure Excursion Rentals
- Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list
- Pick Your Favored kind of books
- What is ‘Auld Lang Syne’? Why we sing this song at midnight on New Year’s Eve.
- Productive CRM Programming for Client Relationship The executives
- How did birds survive while dinosaurs went extinct?
